man Dermatology Society (DDG; Aberer, Kränke, Becker, Bircher, Brasch), the Information Network of Dermatological Clinics (IVDK; Schnuch, Aberer, Brasch), the German Society for Allergology and Clinical Immunology (DGAKI; Przybilla, Biedermann, Werfel), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG (John, Elsner, Diepgen) , the Medical Association of German Allergologists (AeDA; Merk, Fuchs), the Professional Association of German Dermatologists (BVDD; Jung) and the DDG (Trautmann).
Taking the previous version of the guidelines [2] as a basis, the rst author developed an initial dra updated in terms of formal structure and content. Additions and modi cations were then made in the context of an email discussion involving all authors, until a general consensus among the authors was reached.
Taking into account German-language and PubMed medical specialist journals, the authors systematically evaluated the scienti c literature on the topic of contact dermatitis. However, the authors' clinical experience was also taken into consideration. is decision seemed justi ed given that treatment approaches for contact dermatitis have been in use for decades and will continue to form the mainstay of clinical routine in spite of the fact that no e cacy studies according to currently valid criteria (double-blind, prospective, randomized) have been performed to date. us, disregarding empirical knowledge of this kind would have resulted in inadequate recommendations.
Limitations
ese S1 guidelines were developed by the authors to the best of their knowledge and belief. However, the treating physician should review the adoption of these recommendations in each individual case, since deviations from recommended approaches may be necessary on the basis of individual circumstances. Studies in the future may also suggest alternative approaches.
De nition of contact dermatitis
An eczematous reaction is an in ammatory intolerance response characterized by successive and coexistent erythema, blisters, exudation, papules, and aking. e term "dermatitis" is generally used as a synonym for "eczema". is response pattern is caused primarily by toxins that have an external, non-infectious, immunological, chemical, or physical e ect. is is classically the case in contact dermatitis. However, eczematous skin reactions can also be triggered via endogenous pathways or by systemic allergen intake.
From an etiological perspective, a distinction is made between allergic -generally delayed type (type IV) and only rarely immediate type (type 1), as in protein contact dermatitis -and irritant (nonallergic) forms of contact dermatitis. Allergic forms presuppose sensitization to the o ending allergen or a cross-reactive allergen. Irrespective of the varying etiology (type IV or type I allergy or skin irritation), a form of dermatitis develops. e irritant forms are also classi ed as toxic, degenerative, subtoxic, or cumulatively toxic. Many patients exhibit a combination of irritant and allergic mechanisms with an o en synergistic e ect [3] .
Clinical symptoms alone o en do not permit classi cation of the dermatitis as allergic or irritant contact dermatitis.
Acute, subacute, and chronic presentations can be distinguished according to morphology, development over time, and time of exposure to the toxin.
is classi cation is also important for the choice of therapy.
Epidemiology
Allergen-speci c (contact) sensitization is an essential precondition of allergic contact dermatitis. e prevalence of sensitization to individual contact allergens varies widely in Germany, Austria, and German-speaking areas of Switzerland according to patient populations, is partially occupation-related, and subject to special analyses and surveillance [4, 5, 6] . However, it is not possible to draw conclusions about the frequency of contact dermatitis directly from the prevalence of sensitization to contact allergens. e relevance of irritants as the potential causal agents of irritant contact dermatitis has been extensively investigated, particularly in certain occupational groups [7] . e likelihood of developing irritant contact dermatitis rises with the intensity and duration of exposure to the irritant. Depending on the occupational eld investigated, irritant or allergic contact dermatitis represent the forms most commonly seen in terms of occupation-al dermatitis [8] . Irritant contact dermatitis is o en the precursor of further contact sensitization [9] .
Allergic and irritant contact dermatitis are common diseases seen in many countries where they are by no means only work-related and where they generate considerable public-health and socio-economic costs [10, 11, 12] .
Prevalence of contact dermatitis
e proportion of the German population estimated to be a ected by some form of contact dermatitis is estimated at 15 %-20 % [12] . It is not unusual for children to be a ected and some studies show that the incidence is rising among the pediatric population [13, 14, 15] . Contact eczema is also frequently seen in older adults as a result of age-related di erences in exposure, changes in epidermal barrier function, and alterations in immune reactivity [16, 17] . According to a German health survey carried out in 2000 (Gesundheitssurvey 2000 [18] ), the lifetime prevalence of allergic contact dermatitis is around 15 % and the annual prevalence approximately 7 %.
Danish studies in the 1990s reported a lifetime prevalence of hand dermatitis of 17 %, and already in adolescents aged between 12 and 16 years the prevalence was 7 % [19] . In Gothenburg, Sweden, the point prevalence of hand dermatitis among individuals aged between 20 and 65 years was 5.4 % and the 1-year prevalence 10.6 % [20] . On the basis of a review of original articles from the last 30 years, a point prevalence of hand dermatitis of 4 % was determined [21] , whilst a 1-year prevalence of 2 % was given for acute contact allergic dermatitis of the hand. According to this review, the 1-year prevalence of hand dermatitis in general was approximately 10 % [21] . In a patient collective of the Information Network of Dermatological Clinics (IVDK), hand dermatitis accounted on average for approximately a third of all forms of contact dermatitis; assuming an equivalent proportion in Sweden would yield a prevalence of allergic contact dermatitis of 6 % [19] . us, the 1-year prevalence of 7 % determined by the German health survey appears to demonstrate relatively stable development over the decades [18] . Allergic contact dermatitis is undoubtedly a widespread disease with an incidence similar to that of diabetes.
Incidence of contact dermatitis
In the Netherlands, an incidence of 7.9 per 1000 person-years was observed for non-etiologically dened contact dermatitis [22] . Incidences determined for selected occupations are signi cantly | higher [23, 24] . An incidence of allergic contact dermatitis of 28 per 1000 per year was calculated in a collective made up of students at a university dermatological out-patient department in the US [19] . Using urban sample populations, British colleagues calculated an incidence of 0.6 per 1000 per year. If this rate were to be corrected by a factor that takes the consultation rate into consideration, the incidence would stand at 1.6 per 1000 per year. Using a calculation model for a "moderate" scenario (assumptions lying somewhere between the two possible extremes), the incidence of allergic contact dermatitis was estimated at 3 per 1000 per year [25] .
Maxim: As a public health problem, allergic contact dermatitis a ects all age groups with a high prevalence and incidence.
Clinical picture of contact dermatitis

Clinical presentations of contact dermatitis
Tab. 1 shows the "classic" clinical forms of contact dermatitis.
Clinical symptoms depend primarily on whether the dermatitis is acute or chronic, as well as on the toxin involved, type of contact, pathomechanism, and localization, among other factors (Tab. 2) [26] . Although all types of dermatitis generally share common features, the classic eczematous stages in contact dermatitis (allergic and irritant) are most readily identi able. erefore, this particular variant of dermatitis is considered the classic example [26, 27] .
Acute-stage eczematous reaction
Acute contact dermatitis is characterized by a largely uniform metachronous sequence of pathological symptoms over the entire lesion. -Mild form: erythema at the site of exposure to the toxin, contact traces, and itching are possible. -Severe form: ranging from vesicular papules (histologically: spongiotic blisters) to blisters, usually causing strong itching. A feeling of tightness of the skin and even pain may occur. Blister rupture is followed by weeping, scab formation, and later by scaliness, generally culminating in restitutio ad integrum. Spreading reactions are possible in the case of an allergic trigger. Acute irritant contact dermatitis is characterized by: rapid onset (within hours) following generally easyto-identify exposure, rapid clinical course, and usually also rapid resolution; its monomorphic and often highly intensive clinical symptoms (including possible skin necrosis); subjective symptoms perceived more as burning pain than itching; and clearly demarcated borders around the area of contact and the absence of spreading.
Chronic dermatitis
Chronicity occurs when the skin continues to be exposed to the toxin, thereby preventing spontaneous healing of the dermatitis, or when the dermatitis persists even in the absence of the toxin.
From a morphological perspective, there are eczematous plaques with focal emphasis in more exudative or scalier areas. e initially relatively sharp demarcation becomes increasingly indistinct. e skin has a thickened appearance due to the in ltration of in ammatory cells and skin folds become accentuated (licheni cation). e clinical picture is increasingly dominated by hyperkeratoses, rhagades, and licheni cation.
e onset of chronic degenerative contact dermatitis is rst seen a er exposure lasting in some cases for up to years. e initial symptom is generally uncomfortable dryness of the skin, followed by erythema and aking. erea er, it is characterized by a dry, hyperkeratotic-scaly, ssured/rhagade-like lesion of a less exudative nature. It follows a slow clinical course and heals only in a delayed manner, is largely -but not exclusively -restricted to the area of contact, and does not show a tendency to spread. Variables e development of dermatitis varies not only according to its course over time, but also according to body region and is co-determined by the type and aggressivity of the triggering agent and other parameters (Tab. 2). Relevant genetic factors are currently the subject of numerous studies [28, 29, 30, 31, 32, 33, 34, 35] .
|
e varying localizations of dermatitis are not only suggestive of possible triggers, but sometimes also of the pathogenetic mechanisms involved. Typical sites of predilection for the initial symptoms of allergic contact dermatitis include the back of the hand and the lateral sides of the nger. Dermatitis triggered by ultraviolet (UV) light is, at least initially, restricted to areas exposed to light and spares facial areas shaded by the chin, ears, etc., as well as areas of the body covered by hair or clothing. Dermatitis on exposed areas of the body can also be triggered by airborne allergens, such as plant allergens or volatile substances in the workplace (e.g., epoxide resins) [36] (airborne contact dermatitis).
e various localizations of dermatitis can produce speci c morphology. For example, angioedema-like swelling of the eyelids is o en the only manifestation seen in the facial area, whereas dermatitis on the lower legs can appear "striped" following contact with plants, and textile dermatitis is typically worse in areas coming into intense contact with fabric (o en intertriginous areas, e.g., armpits, groin). Due to the thick stratum corneum on the palms of the hands and soles of the feet, microscopic blisters can develop into large eruptions by means of con uence (Cheiropodopompholyx). Occasionally, once healed, post-in ammatory hypo-or hyperpigmentation may be seen. Scarring or granulomas develop only in very rare cases.
In contrast to irritant contact dermatitis, allergic contact reactions may exhibit spreading phenomena. Although the precise pathomechanism of these spreading reactions is unknown, intensive allergen contact and hematogenous distribution of the allergen or generalized activation of immunological effector cells are suspected pathways [37] , among others.
Individual predisposing factors, particularly in chronic-degenerative dermatitis, are of considerable relevance, such as an underlying predisposition to atopic dermatitis or -usually age-or care-relatedexsiccation of the skin. is frequently results in a combined pathogenesis of dermatitis. "Gra ed allergies", i.e., the development of a contact allergy in the setting of an existing chronic-degenerative dermatitis, are not uncommon. Mixed clinical presentations comprising allergic and chronic-degenerative dermatitis are o en challenging to classify from a clinical and di erential diagnostic point of view. Secondary bacterial colonization (frequently with staphylococci, particularly in weeping dermatitis), dermatophytes (notably on hands and feet), or candida infections (body folds, particularly in infants and diabetics), and less commonly viruses make diagnosis di cult and complicate therapy. Pustules in the setting of dermatitis can lead not only to secondary infections, but also to weeping dermatitis in cases where inadequate occlusive ointment treatment is administered.
In brief: Dermatitis seen as the " nal common pathway" of widely varying entities is a ected by multiple variables. Diagnosis requires a di erentiated approach, usually involving patch testing. Table 3 The most important non-eczematous symptoms of contact allergic reactions Erythema multiform-like reactions, e.g., following contact with topical medications (antiphlogistic agents, antibiotics) or plant allergens
Pigmented purpura or pigmented contact dermatitis, e.g., due to colorants and latex allergens Lichen planus-like or lichenoid contact reactions in mucosa to dental allergens (e.g., in chronic metal contact) Bullous, papular-nodular and pustular reactions, particularly to metal Lymphomatoid or primarily dermally localized variants, e. g., to metal or hydroquinone Primarily edematous reactions, e. g., due to PPD or azodyes Granulomatous reactions to metal salts, e.g., in tattoos (DD sarcoidosis: further diagnostic steps may be required!) Scleroderma-like lesions (due to organic solvents) DD, diff erential diagnosis; PPD, para-phenylenediamine | Table 4 Important di erential diagnoses in contact dermatitis 
Non-eczematous clinical presentations of contact allergic reactions
ese may be triggered by epicutaneous, cutaneous, and systemic allergen exposure [27, 37, 38, 39, , 40, 41] . Unusual contact allergens may be relevant [42] .
e most important non-eczematous reaction patterns are shown in Tab. 3.
Note: Skin reactions to external contact agents can sometimes produce a clinical picture that is not suggestive of dermatitis at rst glance.
Diagnosis
Patient history and the clinical picture are crucial to the diagnostic process. e most important differential diagnoses are summarized in Tab. 4 .
Histological analysis of a skin biopsy is indicated in all cases showing atypical symptoms or clinical course.
Patient history includes questions relating to the development of the dermatitis and allergen exposure, as well as an assessment of causality. Once patch test results are available, questions relating to allergen exposure o en need to be repeated in a second patient history. Due to the complexity of possible types of exposure, supplementary questionnaires to aid patient history taking have been developed for a number of occupations [43, 44, 45, 46, 47, 48, 49, 50] . e suspicion that dermatitis has been caused by exposure to an exogenous trigger is formed on the basis of allergen and/or toxin exposure and the clinical picture. In irritant contact dermatitis, the trigger is usually exposure of the skin to an irritant, such as frequent or prolonged contact with water, solvents and cleaning agents, dust, etc., that predominantly cause irritant reactions. e diagnosis of allergic contact dermatitis is made by detecting contact sensitization to causative allergens by means of patch testing. A detailed description of how to perform patch tests and evaluate their relevance is given in the relevant DDG guidelines [51] . It is essential to: use approved test substances (e. g., as in the series of tests recommended by the DKG), apply the patches in a methodically correct manner, and take a reading of reactions by the third day at the latest.
If no plausible result is achieved using a conventional patch test despite suspected contact allergy, modi ed patch testing methods are considered [52, 53, 54, 55, 56, 57, 58] (Tab. 5).
e methods described in Tab. 5 require particular experience and should therefore only be carried out by specialists.
In brief: The diagnosis of contact dermatitis is based on patient history, clinical examination, and skin testing. Additional investigations may be necessary. e lymphocyte-transformation or -stimulation tests (LTT or LST) and their modi cations (e. g., memory lymphocyte immunostimulation assay, MELISA) should be used for scienti c or highly specialized clinical investigations. Performing these tests is technically challenging and the methods are poorly standardized; thus, LTTs should remain the reserve of specialist laboratories that have particular experience with these test methods and the interpretation of their results. In the absence of a critical evaluation of LTT results in comparison with patch test results, possibly also a repeated open application test (ROAT) or exposed control person, their relevance is questionable and should not form the basis for prophylactic or therapeutic measures [60, 61, 62] . In exceptional cases involving very strong patch test reactions to para-phenylenediamine (PPD), LTTs can be helpful in preventing reactions due to cross-sensitization in further testing [61, 63] . Other in vitro methods for the diagnosis of contact allergies are not validated.
e guidelines of the German Association of Scienti c Medical Societies (AWMF) (register number: 061/017, Renz et al.) state in this regard: "In high concentrations, some contact allergens can also function as mitogens (i. e., obligatory stimuli), making individual titration necessary. Whether the of-| Table 5 Modi cations and additions to patch testing For the "strip" patch test, the horny layer is reduced prior to allergen application
For the repeated open application test (ROAT), a suspected allergen is repeatedly applied openly over several days Although the atopy patch test enables atopic individuals to be investigated for airborne and food allergens following late phase reactions [52] , the test has not yet been suffi ciently validated [3] [59] . For certain substances (e.g., drug preparations approved for intravenous use) intracutaneous testing with delayed readings can be helpful; however, cross-center validation is still lacking for this method Additional scratch testing can be helpful if adequate transepidermal administration of the test substance is not possible with patch testing. Delayed readings over several days are necessary ten poor speci city of LST for the analysis of metal compounds can be attributed to non-optimized conditions is unclear. Especially good correspondence between LST and patch testing is achieved for nickel sulfate in particular. However, from a dermatological point of view, there is no clinical indication to favor the complex in vitro test that is not validated for most allergens over the patch test, thereby leaving the real value of the LST in relation to contact allergens squarely in the domain of scienti c investigations (and further development of the test system). Indiscriminate use of LST (or modications thereof, such as MELISA) in the diagnosis of mercury allergies should be rejected." ere is currently no useful diagnostic test for the direct identi cation of irritant contact dermatitis [64] . Alkaline resistance testing, the Nitrazine yellow swab test, or measuring transepidermal water loss do not represent reliable diagnostic aids. us, the diagnosis of irritant contact dermatitis is made on the basis of patient history and clinical pictureonce possible causal contact sensitization has been excluded -and can be indirectly con rmed by subsequent resolution following cessation of toxin exposure.
Treatment
Patient information
e successful treatment of contact dermatitis requires patient cooperation. e information provided to the patient and their mastery of the treatment, as well as care and protection measures, can contribute signi cantly both in terms of treatment and prophylaxis, particularly where occupation-related dermatitis triggers are relevant [65, 66, 67] .
Avoiding the noxa
Contact dermatitis is triggered by exogenous toxins in the vast majority of cases. e most important therapeutic approach, therefore, is to cease causal exposure -no form of symptomatic treatment can substitute for this approach. Attempts to induce tolerance to contact allergens by means of immunotherapy have been hitherto unsuccessful [7, 68] .
Where it is not possible to fully eliminate or avoid a triggering contact substance (allergen or irritant) in the individual's immediate environment, protective measures to prevent renewed skin contact are indicated. ese include: personal protective clothing (o en primarily protective gloves in the case of hazardous activities), work-related precautionary measures (modifying work processes, avoiding wet/ humid work conditions, using extraction systems), and consistent stage-related treatment [69, 70] .
ese measures need to be tailored to the individual situation (toxic substance, type of exposure). Prolonged use of gloves should be avoided due to their occlusive e ect, although these e ects are apparently milder than originally assumed [71] . Adjuvant use of suitable skin barrier creams can be helpful [72, 73] .
e selection of gloves and barrier creams should be made on the basis of their e cacy against the relevant toxins [74] .
Dietary measures can be helpful in cases where a systemic hematogenous triggering of contact dermatitis in the setting of high-grade sensitization to an orally-ingested contact allergen is diagnosed (as evidenced by patient history, patch testing, exclusion diet, and diagnostic provocation). Under this premise, a low-nickel diet may improve symptoms in individuals allergic to nickel [75, 76, 77, 78] , whilst chelating agents have also been described as helpful [79, 80] .
Maxim: Avoiding the diagnostically determined noxa(e) is crucial.
Symptomatic treatment of contact dermatitis
Topical treatment is generally su cient. As with other in ammatory dermatoses, the base in which the active substance is applied must be tailored to the severity of the dermatitis. Acute dermatitis is generally moist and needs to be treated with a hydrophilic preparation (gel, lotion, cream), whereas chronic disease is more likely to require a water-inoil-based preparation (ointment). Needless to say, the base should not contain any allergens that may be relevant to the patient.
Corticosteroids e e cacy of topical treatment with class-II or -III corticosteroids in acute allergic contact dermatitis is undisputed [81] ; stronger preparations are required only in exceptional cases. However, weaker preparations at least do not always produce any detectable e ect in irritant contact dermatitis [53] . e selection of a suitable corticosteroid with the appropriate e cacy should be made on the basis of the localization of skin lesions, as well as the severity and acuteness of the dermatitis, whilst bearing the therapeutic index in mind [82, 83] . Where long-term therapy is indicated, preparations bearing low risk of atrophy (e. g. mometasone furoate, methylprednisolone aceponate, hydrocortisone butyrate) are preferred [84, 85] .
e general principles governing the use of corticosteroids apply equally to their use in the treatment of contact dermatitis. e known side e ects of topical treatment must be borne in mind when deciding upon the type and duration of treatment.
Hence, topical corticosteroids represent the medication of rst choice for the symptomatic treatment of contact dermatitis.
Calcineurin antagonists
In Germany, Austria, and Switzerland, calcineurin antagonists are only approved for the treatment of atopical dermatitis.
ey are less e ective than strong corticosteroids in manifest contact dermatitis [87, 88, 89, 90, 91, 92, 96] . However, if long-term use is indicated, topical calcineurin antagonists may be bene cial in contact dermatitis compared to corticosteroids, particularly in sensitive areas of the skin (e. g., face, intertriginous areas), since they carry no atrophy risk [93] . With regard to safety, the reader is referred to the AWMF guidelines of the DDG on topical calcineurin antagonists and neurodermatitis [85, 94] .
Ultraviolet therapy
Short-wave ultraviolet light (UVB) and PUVA (psoralen plus UV-A) are e ective in chronic dermatitis, most notably in hand dermatitis [70, 95, 96, 97, 98] . In some forms of hand dermatitis, topical application of psoralens is advisable in the context of PUVA therapy in order to intensify the therapeutic e ect. It appears possible to achieve a certain degree of "protective hardening" using UVB [101] . Positive data are also available on the use of UVA1 and narrow-band UVB, particularly in hand dermatitis [102, 103, 104] .
Other external agents
Due to its antiphlogistic and antiproliferative e ects, the use of coal tar as a follow-up treatment is still reasonable today in cases where other external agents are ine ective or declined by the patient.
ere is no evidence to support the fear that local treatment with coal tar is carcinogenic [105, 106, 107, 108, 109] . However, the known side e ects of coal tar treatment (skin irritation and discoloration, acnegenic e ect, photosensitization) must be borne in mind. Antiseptic agents such as triclosan, polyhexanide, octenidine, etc., are helpful in the elimination of germs in pathogenic microbial colonization. Iontophoresis can be bene cial in dyshidrotic dermatitis [110] . So X-ray therapy and Grenz ray therapy have proven to be helpful in the treatment of dermatitis [111, 112, 113, 114] . However, due to the harmful cumulative e ects of X-rays to the skin, these methods are in principal contraindicated today and only justi ed in exceptional cases. e efcacy of topical non-steroidal antiphlogistic agents in contact dermatitis has not been su ciently proven; in addition, there is a relevant risk of contact sensitization to these substances when used topically in dermatitis [115, 116] . Although Bufexamac has had its approval withdrawn by the European Medicines Agency due to its sensitization potential, it is still available in Switzerland and outside Europe. Moreover, many other substances for which no published data on e cacy are available are nevertheless used and recommended for the treatment of dermatitis.
e same is true for antihistamines.
Systemic treatment
Systemic treatment may become necessary in cases where local treatment is insu ciently e ective. It is essential to take the speci c side-e ects pro le of the agents used into consideration. Short-term systemic corticosteroid therapy (from 3 days up to 2 weeks) may be indicated, particularly for extensive contact dermatitis in acute, severe, and/or therapy-refractory cases, frequently in the case of systemic contact dermatitis (hematogenous contact dermatitis). e usual rules on systemic administration of corticosteroids apply here. Systemic administration of alitretinoin may be helpful in chronic hand eczema [117, 118, 119, 120] . In this regard, the reader is referred to the guidelines on hand dermatitis [1] . Insu cient data is available to date on the long-term e ects [119] . Cyclosporine is currently the drug of rst choice in the treatment of severe, therapy-resistant atopic dermatitis in adults, an indication for which it is approved. Long-term oral administration of cyclosporine A can be helpful in patients with therapy-resistant hand dermatitis [121, 122] . Other immunomodulators, such as azathioprine, mycophenolate mofetil, or methotrexate are also used for atopic dermatitis o -label (but only if cyclosporine is ine ective or contraindicated), and can also be considered for contact dermatitis [94, 123, 124] .
Basic therapy and skin protection
Follow-up treatment with basic moisturizing agents to promote skin barrier regeneration and protect against recurrence, combined with the use of skin protection creams, is bene cial when individually tailored to skin status and skin exposure [125, 126, 127] . On the other hand, preparations containing unsuitable levels of water and fat or allergenic components may delay the resolution of dermatitis or even intensify the e ect of substances harmful to the skin [127] . Although skin protection training is bene cial in the case of hazardous occupational ex-posure [128] , the e ectiveness of skin protection creams alone under working conditions has not be unequivocally proven [129] . Complete restoration of barrier function is not expected until several weeks a er the clinical resolution of contact dermatitis. However, the bene cial e ect of moisturizers is measurable [130] .
Evidence of therapeutic e cacy
Only a small number of prospective, randomized, double-blind, controlled studies meeting current criteria have proven the e cacy of the contact dermatitis treatments mentioned here in su ciently large patient populations.
Relevant data supporting e cacy is only available for the use of topical corticosteroids and systemic administration of alitretinoin in hand dermatitis [84, 131, 118] . However, this does not mean by implication that the other treatment forms discussed here are ine ective. Although studies on conventional therapy methods in dermatitis may be lacking for many reasons, the long-term clinical experience of experts in terms of e cacy is undisputed.
Note: Individually tailored systemic therapy should be considered when topical therapy is either ine ective or unfeasible.
Reporting dermatitis
It is generally necessary to establish whether a case of contact dermatitis has been triggered by occupational exposure. Where work-related causality is possible, a dermatological report is drawn up -with the patient's consent -to the relevant statutory accident insurance (e.g., employer's liability insurance association) [132] . However, if the reasonable suspicion of an occupational disease has already been con rmed, i.e., ceasing the activity appears the only option once all avenues of prevention have been explored, it is legally required of the treating physician to report an occupational disease (in Germany, using form F6000) [133] .
